Hangzhou Biotest Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,251	1,476	1,591	1,907	1,940	1,368
Short-Term Investments	-	-	47.04	10	-	-
Trading Asset Securities	13.93	13.76	60.26	-	100.06	360.84
Cash & Short-Term Investments	1,265	1,489	1,698	1,917	2,040	1,729
Cash Growth	-18.97%	-12.30%	-11.43%	-6.01%	18.02%	561.86%
Accounts Receivable	96.07	89.37	97.46	61.89	38.82	146.91
Other Receivables	1.75	3.44	4.27	2.8	1.6	8.32
Receivables	97.82	92.81	101.73	64.68	40.42	155.23
Inventory	69.73	69.68	73.4	99.32	135.2	141.7
Prepaid Expenses	-	-	0.68	-	-	-
Other Current Assets	13.93	9.59	3.85	5.37	19.6	7.2
Total Current Assets	1,446	1,661	1,878	2,087	2,235	2,033
Property, Plant & Equipment	565.53	540.87	408.81	261.58	244.68	231.02
Long-Term Investments	85.87	41.67	19.3	2.84	40	40
Other Intangible Assets	267.32	269.31	275.16	208.71	213.71	20.35
Long-Term Deferred Tax Assets	16.73	10.1	11.8	14.44	13.16	3.01
Long-Term Deferred Charges	-	-	-	0.11	0.21	0.29
Other Long-Term Assets	23.96	15.99	9.15	5.08	4.54	104.13
Total Assets	2,405	2,539	2,602	2,580	2,752	2,432

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	102.11	98.67	56.45	58.35	88.72	224.32
Accrued Expenses	9.65	18.61	19.08	20.02	25.94	26.32
Short-Term Debt	0.6	0.49	0.44	0.59	0.35	5.64
Current Portion of Leases	-	-	-	2.45	5.1	2.28
Current Income Taxes Payable	2.36	0	0.02	-	-	39
Current Unearned Revenue	14.18	15.16	7.39	47.16	44.68	18.56
Other Current Liabilities	23.13	25.05	95.23	20.85	6.28	1.44
Total Current Liabilities	152.11	157.98	178.62	149.43	171.08	317.56
Long-Term Debt	99.5	-	-	-	-	-
Long-Term Leases	-	-	-	-	2.19	4.55
Long-Term Unearned Revenue	9.33	10.19	11.17	8.69	6.43	1.25
Long-Term Deferred Tax Liabilities	-	-	-	0.71	1.16	-
Other Long-Term Liabilities	-	-	-	-	8.43	-
Total Liabilities	260.94	168.17	189.79	158.82	189.29	323.36

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	149.33	149.33	106.67	106.67	106.67	106.67
Additional Paid-In Capital	752.57	751.68	790.45	813.33	814.94	814.94
Retained Earnings	1,365	1,486	1,543	1,510	1,638	1,185
Treasury Stock	-127.45	-18.07	-31.61	-14.76	-	-
Comprehensive Income & Other	1.99	1.24	0.94	-0.36	1.21	0.7
Total Common Equity	2,141	2,370	2,409	2,415	2,561	2,107
Minority Interest	3.57	1.47	2.87	5.51	1.04	1.05
Shareholders' Equity	2,145	2,371	2,412	2,421	2,562	2,108
Total Liabilities & Equity	2,405	2,539	2,602	2,580	2,752	2,432

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	100.18	0.49	0.44	3.04	7.64	12.47
Net Cash (Debt)	1,164	1,489	1,698	1,914	2,032	1,716
Net Cash Growth	-25.37%	-12.30%	-11.31%	-5.81%	18.43%	586.22%
Net Cash Per Share	8.73	10.28	11.52	12.83	13.60	14.15
Filing Date Shares Outstanding	155.13	102.38	150.87	146.38	149.33	149.33
Total Common Shares Outstanding	155.13	102.38	150.87	148.7	149.33	149.33
Working Capital	1,294	1,504	1,699	1,937	2,064	1,715
Book Value Per Share	13.80	23.15	15.97	16.24	17.15	14.11
Tangible Book Value	1,874	2,100	2,134	2,207	2,348	2,087
Tangible Book Value Per Share	12.08	20.52	14.15	14.84	15.72	13.97
Buildings	-	285.72	284.05	193.65	194.71	189.13
Machinery	-	96.77	96.17	90.92	81.61	66.19
Construction In Progress	-	229.58	87.23	39.65	9.85	-